-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Assumes Citius Pharmaceuticals at Buy, Announces Price Target of $4

Benzinga·05/18/2026 15:06:29
Listen to the news
HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy rating and announces Price Target of $4.